Progress in Liver and Bile Duct Cancer: New Insights from ESMO 2025
This year’s ESMO Congress showcased key advances in the treatment of liver and bile duct cancers. While some new immunotherapy combinations did n...
Advancing Patient-Centred Care at UEG Week 2025
UEG Week 2025 in Berlin provided a valuable chance to deepen collaboration with healthcare professionals, researchers, and patient advocates. The f...
EU HTA Has Begun: What New Joint Clinical Assessments Mean for Access to Digestive Cancer Medicines
From 12 January 2025, new oncology medicines will undergo EU-wide Joint Clinical Assessments (JCAs). This coordinated evaluation aims to accelerate...
Personalised Progress in Gastric Cancer: Highlights from ESMO 2025
This year at ESMO, new research revealed improved methods to personalise treatment for gastric cancer. These approaches could help patients achieve...
Key Takeaways from ESMO GI 2025 on Pancreatic Cancer
Promising new therapies are emerging. Daraxonrasib, a KRAS-targeting pill, is in Phase 3 trials after earlier encouraging results and FDA Breakthro...
DiCE Grants — Autumn 2025
DiCE opens Autumn 2025 grants: unrestricted operational support for Full and Associate Members, plus the €5,000 Wolfram Nolte Memorial Award for ...
VOICE: A Life-Changing Training in Cancer Research
Patient advocates joined VOICE in London for a week of immersive learning at Barts Cancer Institute. Exploring cancer biology, research methods, an...
EU-CIP Project Launches to Improve Access to Cancer Information Across Europe
The EU-CIP project launched on 12–13 June in Berlin. This EU-funded initiative will provide clear, reliable cancer information for patients, fami...
Promising Advances in Pancreatic Cancer: ASCO 2025 Highlights
Phase III PANOVA-3 trials show that Tumour-Treating Fields Improve Overall Survival Final data from the Phase 3 PANOVA-3 study of tumour treating f...
Amplifying the Patient Voice: Reflections from the WECAN Academy 2025
DiCE Patient Ambassador Mila Ogalla Toledo shares her experience at the WECAN Academy 2025 in Rome—a three-day training for cancer advocates acro...